Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Dermatologic 1Breast 1

Conditions

Melanoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Nivolumab 10pembrolizumab 6Ipilimumab 6Niacinamide 3Magnetic Resonance Spectroscopy 3Itraconazole 3Cyclophosphamide 3Biopsy 3resiquimod 2encorafenib 2durvalumab 2calcipotriene 2binimetinib 2aldesleukin 2Radiotherapy 2Oncolytic Virotherapy 2Niacin 2MART-1 Antigen 2Interleukin-2 2Imiquimod 2HhAntag691 2Fluorouracil 2Ascorbic Acid 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Propranolol × Dermatologic × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡